PROTEOME SCIENCES PLC 
By
Proteome Sciences has established an extensive portfolio of
patented plasma biomarkers of stroke and other brain
damage-related disorders discovered in partnership with the
Biomedical Proteomics Research Group at the University of
Geneva. These markers are rapidly elevated in blood of
patients undergoing both haemorrhagic and ischaemic strokes
and offer the potential to identify those patients that would
most benefit from thrombolytic treatment within the first 3
hours after onset of symptoms. The research with BPRG has
shown that a panel of 5 blood proteins is able to accurately
rule out 90% [9 out of 10] of patients that have not had a
stroke but who may currently be misdiagnosed in primary care
and allows 90% [9 out of 10] of genuine strokes to be
confirmed within minutes of the onset of symptoms. Together,
these results have the potential to transform the management
of acute stroke and ensure more patients receive thrombolytic
therapy. These provide a highly effective way to minimise
long-term disability in ischaemic stroke, reduce the cost of
care and considerably improve the quality of life for stroke
patients and their families.
Under the terms of the Agreement Randox will develop products
for early diagnosis of stroke and subsequent monitoring of
treatment outcomes. Financial terms provide Proteome Sciences
with seven digit (US dollar) license and development
milestones together with double digit royalties on sales.
The clinical discovery and validation of the stroke
biomarkers was led by Prof Jean-Charles Sanchez, Director of
the University of Geneva Biomedical Proteomics Research Group
who commented "The discovery and validation of a panel of
early stroke biomarkers in blood opens the way for rapid
detection and selection of treatment that will have profound
benefits for patients, their families and carers. We have
recently studied the potential impact of using just one of
these markers, GST-Pi, and found it could increase the number
of treated stroke patients five-fold."
Dr. Ian Pike, Chief Operating Officer of Proteome Sciences
said "We are pleased to be partnering our advanced stroke
biomarkers with Randox who are rapidly developing a strong
presence in the CNS area. Their track record of new product
introductions has been impressive and we see their testing
platforms as an ideal setting for rapid stroke
diagnosis."
Dr. Peter FitzGerald, Managing Director at Randox commented
"the addition of the Proteome Sciences stroke biomarkers will
add significantly to the range of diagnostic products we
offer in the cardiovascular disease field. Our ability to
deliver these novel biomarkers to healthcare providers using
our Biochip Array systems will enable stratification of
patients for appropriate treatment and contribute to a
reduction in healthcare costs. The stroke biomarkers will be
offered to hospital laboratories through our global
distribution network in 130 countries
Christopher Pearce, Chief Executive of Proteome Sciences said
"The stroke biomarkers licensed to Randox have the ability to
transform the way stroke is managed and ensure that
considerably more patients receive treatment early. This will
reduce the levels of disability, lower the cost of care and
improve patient outcomes. We are delighted that the
importance of our proprietary biomarkers is being properly
recognised in diagnostics and drug development. Whilst
licensing to companies like Randox remains a key component of
our business, we also provide direct testing services through
our
ISO 9001:2008 certified facility and rapidly increased the
number of biomarkers where we had assay coverage to around 50
by the end of 2011 and this number will double in 2012 with
revenue reflected through PS Biomarker Services™."
Christopher Pearce, Chief Executive Officer Tel: +44 (0)1932
865065
Dr. Ian Pike, Chief Operating Officer
James Malthouse, Finance Director
Stephen Keys/Camilla Hume Tel: +44 (0)20 7 397 8900
Public Relations FTI Consulting IKON Associates
Ben Atwell / Simon Conway / Mo Noonan Adrian Shaw
Tel: +44 (0)20 7269 7116 Tel: +44 (0)1483 271291
Proteome Sciences is a global leader in applied proteomics
and peptidomics offering high sensitivity, proprietary
technologies for protein and peptide biomarker discovery,
validation and assay development.
Its PS Biomarker Services™ uses isobaric and isotopic Tandem
Mass Tag® (TMT®) workflows
developed on the latest Orbitrap Velos and TSQ Vantage mass
spectrometers to deliver rapid, robust and reproducible
biomarker assay development for customers in the
pharmaceutical, diagnostic and biotechnology sectors.
Services are provided from its ISO 9001: 2008 accredited
facilities in Frankfurt, Germany. By combining Selected
Reaction Monitoring (SRM) and TMT workflows highly
multiplexed assays can be developed rapidly and are suitable
for screening hundreds of candidate biomarkers in larger
validation studies and can be transferred for immunoassay
development. The Company's own research has discovered a
large number of novel protein biomarkers in key human
diseases and is focused mainly in
neurological/neurodegenerative conditions and in cancer. It
has discovered and patented blood biomarkers, including
Alzheimer's disease, stroke, brain damage and lung cancer for
diagnostic and treatment applications that are available for
license or are already outlicensed. Proteome Sciences, based
in Cobham, UK, with facilities in London and Frankfurt,
delivers outsourced proteomics services and proprietary
biomarkers/biomarker assays to pharmaceutical, biotechnology
and diagnostics companies.
Visit: http://www.proteomics.com.
Randox Laboratories (Randox) is a market leader within the in
vitro diagnostics industry and has 30 years' experience in
developing and manufacturing high quality products for
laboratories worldwide. Our extensive product portfolio
offers complete solutions within the fields of clinical
chemistry, forensic toxicology, veterinary, drug residues,
life sciences, oncology, molecular diagnostics and internal
and external quality control.
Our innovative approach to diagnostics has enabled the
development of a wide range of products including our
bench-top clinical chemistry analyzers, the RX series. The
advanced functionality of each analyzer ensures outstanding
flexibility, optimum reliability coupled with a comprehensive
test panel and cost saving features. The comprehensive range
of RX analyzers offers high quality testing to all sizes of
laboratories.
Randox has also developed a full range of immunoassay
analyzers. They include the Evidence, Evidence Investigator,
Evidence MultiStat and Evidence Evolution. Each system
incorporates revolutionary Biochip Array Technology that
allows simultaneous detection of multiple analytes from a
single patient sample. The multiplex analyzers offer rapid
testing, advanced consolidation and high quality results. The
extensive biochip test menu includes both protein and DNA
biochips, offering a range of over 215 different
biomarkers.
Our goal is to 'revolutionize healthcare through continuously
improving diagnostic solutions'. We continue to achieve this
year after year due to our commitment and significant
re-investment in Research and Development. Our large support
network of staff allows us to develop and perfect
revolutionary products, specifically designed to provide more
efficient, higher quality and reliable results, ensuring
patients receive the right diagnosis at the right time.
Visit: http://www.randox.com
|
distributed by
|
